Navigation Links
Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
Date:4/16/2008

President and Chief Scientific Officer. "We reasoned that if rHuPH20 hyaluronidase could rapidly disperse, dilute and systemically absorb bisphosphonates, it could prevent local irritation and facilitate conversion from intravenous infusion to a more convenient subcutaneous route of administration. These pre-clinical findings support this program's objective of developing what would be the only SC bisphosphonate on the market, in the event of continued success." The Company plans to bring its SC bisphosphonate program into the clinic in the third quarter of this year.

Bisphosphonates are a class of molecules that bind to mineralized bone matrix and inhibit bone resorption. Currently, there are oral and intravenous bisphosphonates. Oral Bisphosphonates often cause gastrointestinal side effects and require a cumbersome dosing regimen. The gastrointestinal side effects of oral bisphosphonates is a significant cause of patient non-compliance to prescribed therapy. Certain bisphosphonates are indicated for the treatment of osteoporosis and skeletal metastases, but can only be administered today by intravenous infusion. As such, patients often have to travel to an infusion center or see a specialist to receive their intravenous bisphosphonate infusion. Subcutaneous injections of bisphosphonates are not considered feasible due to injection site toxicity in the skin and/or impractical injection volumes.

The recombinant protein, rHuPH20, is a human hyaluronidase enzyme that increases the dispersion and systemic absorption of locally injected drugs by temporarily degrading hyaluronan under the skin.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluroni
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014 Research and ... Equipment Market Current Trends, Opportunities - Global Forecast to ... In this report, the global dental equipment market is ... dental systems and equipment market is expected to register ... during the forecast period (2014 to 2019). This high ...
(Date:10/25/2014)... 24, 2014  The National Association of Drug ... achieved by Kentucky,s real-time, ... The National Precursor Log Exchange (NPLEx) system automatically ... sale and helps flag meth offenders for law ... up NPLEx "watch lists" that notify them via ...
(Date:10/25/2014)... 2014 Burzynski Research Institute, Inc. (BRI) announced ... has given the company permission to conduct an open-label ... 3 months of age with a diffuse intrinsic brainstem ... of five treatment groups based on their age and ... DIPG. The primary study endpoint is a decrease in ...
Breaking Medicine Technology:Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 2Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 3Kentucky's NPLEx Technology Making Significant Progress 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2
(Date:10/25/2014)... supply to an arm or a leg before heart surgery ... to a new study. "During heart surgery we ... be able to operate on it. After some time without ... energy because it doesn,t get oxygen. When we shut off ... arm or a leg, the body prepares for an upcoming ...
(Date:10/25/2014)... -- Researchers who discovered antibiotics in farmed and ... concern. The use of antibiotics in animals, ... contribute to the development of antibiotic-resistant bacteria that ... the study. Each year in the United ... and kill about 23,000, according to the Infectious ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... developed that spot increased risks for certain cancers, one might ... screened. But a new study suggests that, at least ... found out their genes doubled their risk of colon cancer ... get screened. "It didn,t make any difference, not at ...
(Date:10/22/2014)... On Saturday, October 25, 2014, the Brownsville Community ... and fitness fair ¡Vive tu vida! Get Up! Get Moving!®. ... for better health and wellness for people of all ages ... to the public, will be held at Dean Porter Park, ... 1:00 pm. , “¡Vive tu Vida! Get Up! Get ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Isabel ... of Allied Health Professions (ASAHP) Conference on October 22-24 ... CEO will participate in a panel discussion on Technology ... , Isabel Healthcare provides a diagnostic decision support tool ... the diagnosis skills of students and clinical learners. The ...
Breaking Medicine News(10 mins):Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2
... may offer a new option to treat about 50 ... signaling of the epidermal growth factor receptor (EGFR), according ... Comprehensive Cancer Center. Rapidly dividing cancer cells require ... fatty acids also provide an alternative energy source for ...
... A new study published by The University of Western ... and unpaid work report higher average measures of happiness and ... ,shared roles, category, where each partner,s unpaid work is within ... growing category that now represents more than 25 per cent ...
... their looks, and in what ways? A team of researchers ... found that yes; attractive people do tend to have more ... This seems like common sense, and might be why we ... attractive. However, the study, published in this month,s issue of ...
... Humanic ... response to demand for increased technology solutions from its clients, Self Service Applicant (APSS) ... matters. , ... NJ (PRWEB) December 15th 2009 -- Humanic Design, a leading provider of Human Resource ...
... may spot people in need of statins, researchers say ... normal levels of LDL (bad) cholesterol still need to ... to identify those who may benefit from cholesterol-lowering statin ... stroke and death, say U.S. researchers. , "This study ...
... and LOS ANGELES, Dec. 15 Comcast Corporation and Stand ... first-ever video-on-demand (VOD) initiative Stand Up 2 Cancer On ... innovative cancer research. Debuting exclusively on Comcast beginning December ... feature an extraordinary library of musical entertainment including hundreds of ...
Cached Medicine News:Health News:Targeting brain cancer cell metabolism may provide new treatment 2Health News:Targeting brain cancer cell metabolism may provide new treatment 3Health News:The importance of attractiveness depends on where you live 2Health News:Humanic Design is Pleased to Announce Application Self Service (APSS) to its Product Suite to Empower Organizations with Automation 2Health News:Normal Cholesterol Doesn't Guarantee Healthy Heart 2Health News:Comcast and Stand Up To Cancer Launch First-Ever Video-on-Demand Effort to Broaden Awareness and Raise Funds for Cancer Research 2Health News:Comcast and Stand Up To Cancer Launch First-Ever Video-on-Demand Effort to Broaden Awareness and Raise Funds for Cancer Research 3Health News:Comcast and Stand Up To Cancer Launch First-Ever Video-on-Demand Effort to Broaden Awareness and Raise Funds for Cancer Research 4Health News:Comcast and Stand Up To Cancer Launch First-Ever Video-on-Demand Effort to Broaden Awareness and Raise Funds for Cancer Research 5
Straight shafts with fine Pierse type tips on a 5mm platform; In Titanium...
Smooth colibri tip; In Titanium....
Gently curved 5mm Platform With 12, 0.12mm Teeth; In Titanium....
Angled tip, 0.3mm triangular grasping tips; In Titanium....
Medicine Products: